Name Dr Sarah Brown
Job Title Demonstrator
Faculty Faculty of Science and Engineering
School School of Pharmacy
Subject(s) Pharmaceutical Science
Tel 01902 321130
Email Sarah.Brown@wlv.ac.uk

placeholder

After completing my undergraduate degree in Biochemistry at the University of Salford I did a PhD at the University of Manchester where I worked in the Leukaemia Research Fund laboratory and investigated the phenotypic, morphological, and functional comparison between normal and leukaemia derived dendritic cells.

I joined the University of Wolverhampton in 2005 as a Research Fellow investigating the potential of using the anti-alcoholism drug disulfiram in combination with copper as a novel chemosensitiser for breast cancer and brain tumour chemotherapy.

In 2012 I was appointed as a Demonstrator in the School of Pharmacy

Cell and molecular biology: Extensive cell culture • cytotoxicity assays • flow cytometry techniques (apoptosis, cell cycle, ROS, protein expression) • western blotting • EMSA • separation/isolation of cell populations • immuno-fluorescence techniques • confocal imaging • live cell imaging • transfections • dual reporter gene luciferase assays • clonogenic studies 

Investigating the potential of using the anti-alcoholism drug disulfiram (DS) in combination with copper (Cu) as a novel chemosensitiser for breast cancer and brain tumour chemotherapy.  DS-Cu can simultaneously modulate the anti-apoptotic NFkB (inhibits) and pro-apoptotic ROS-JNK (activates) pathways to improve the cytotoxicity of a conventional anticancer drugs to cell lines and aldehyde dehydrogenase (ALDH) positive stem-like-cells.  DS-Cu modulates the ROS–MAPK and NFκB pathways and targets cancer cells with cancer stem cell-like properties

Brown S., Hutchinson CV., Aspinall-O'Dea M., Whetton AD., Johnson SM., Unwin KR., Burthem J. (2014) Monocyte-derived dendritic cells from chronic myeloid leukaemia have abnormal maturation and cytoskeletal function that is associated with defective localisation and signalling by normal ABL1 protein. European Journal of Haematology 2014 Mar 11. doi: 10.1111/ejh.12306. [Epub ahead of print]

Kannappan, V., Brown, S., Liu, P., Tawari, PE., Armesilla, AL., Darling, JL., Wang, W. (2014) Aldehyde dehydrogenase activity induces chemoresistance in glioblastoma cell lines. In preparation to submit to British Journal of Cancer

Liu, P., Brown, S., Kannappan, V., Tawari, PE., Jiang, W., Armesilla, AL.,  Darling, JL., Wang, W. (2014) Tackling hypoxia-induced NFκB activation to target breast cancer stem cells In preparation to submit to Carcinogenesis

Liu, P., Kumar, IS., Brown, S., Kannappan, V.,  Tawari, PE., Tang, JZ., Jiang, W., Armesilla, AL.,  Darling, JL., Wang, W. (2013) Disulfiram targets cancer stem like cells and reverses resistance  and cross-resistance in acquired paclitaxel –resistant  triple-negative  breast cancer cells. British Journal of Cancer  2013 Oct 1: 109, 1876-1885

Liu, P., Brown, S., Channathodiyil, P., Kannappan, V., Armesilla, AL., Darling, JL., Wang, W. (2013) Reply to the letter to the Editor: Comment on ‘Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells’. British Journal of Cancer 2013 Mar 5; 108, 994 (joint first author)

Liu, P., Brown, S., Goktug, T., Channathodiyil, P., Kannappan, V.,  Hugnot, JP., Guichet, PO., Bian, X., Armesilla, AL., Darling, JL.,  Wang, W. (2012)  Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. British Journal of Cancer 2012 Oct 23;107(9):1488-97 (joint 1st author)

Baggott, R., Mohamed, TMA.,  Oceandy, D., Holton, ML., Blanc, MC., Roux-Soro, SC., Brown, S., Brown, JE.,  Cartwright, EJ., Wang, W., Neyses, L., Armesilla, AL. (2012) Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells. Carcinogenesis 33 (12): 2362-2368

Özkan, M., Mutiso, PBC.,  Nahar, L., Liu, P.,  Brown, S., Wang, W.,  Sarker, SD. (2012).  Zanthoxylum usambarense (Eng.) Kokwaro (Rutaceae) extracts inhibit the growth of the breast cancer cell lines MDA-MB-231  and MCF-7, but not the brain tumour cell line U251 in vitro. Phytotherapy Research 2013 May;27(5):787-90

Yip, NC., Fombon, IS.,  Liu, P., Brown, S., Kannappan, V.,  Armesilla, AL.,  Xu, B.,  Cassidy, J., Darling, J.,  Wang, W. (2011) Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. British Journal of Cancer 104; 1564–1574